Orexo AB has entered into an agreement with AstraZeneca for its OX-CLI preclinical program for the potential treatment of respiratory diseases. AZ has been granted rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AZ also has an option to acquire the compounds, subject to a full asset transfer agreement, under which Orexo will receive development milestones and royalties on future revenues. Financial terms were not disclosed.   “Our OX-CLI prog...